Trastuzumab BS for intravenous infusion 150 mg “Daiichi Sankyo” is a biosimilar of trastuzumab (genetical recombination), produced by Daiichi Sankyo. This injectable drug (YJ code: 4291446D2020) is supplied as 150mg per bottle with solution, indicated for HER2-positive breast cancer and metastatic gastric cancer.
Trastuzumab BS for intravenous infusion 150 mg “Daiichi Sankyo”
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →